Defensins constitute a major class of cationic antimicrobial peptides in mammals and vertebrates, acting as effectors of innate immunity against infectious microorganisms. It is generally accepted that defensins are bactericidal by disrupting the anionic microbial membrane. Here, we provide evidence that membrane activity of human a-defensins does not correlate with antibacterial killing. We further show that the a-defensin human neutrophil peptide-1 (HNP1) binds to the cell wall precursor lipid II and that reduction of lipid II levels in the bacterial membrane significantly reduces bacterial killing. The interaction between defensins and lipid II suggests the inhibition of cell wall synthesis as a novel antibacterial mechanism of this important class of host defense peptides.
Introduction
Defensins form a large subfamily of cationic antimicrobial peptides that kill a broad range of microorganisms [1] [2] [3] [4] . Human defensins are cysteine-rich, cationic peptides with molecular masses ranging from 3 to 5 kDa. Based on the connectivity of the six conserved cysteine residues and sequence homology, human defensins are classified into a and b families. Both families of defensins have similar three-dimensional structures as determined by X-ray crystallography and NMR studies [5] [6] [7] [8] [9] , sharing a common fold of three-stranded anti-parallel b-sheets constrained by three intra-molecular disulfide bonds. Human defensins were discovered originally as natural peptide antibiotics in neutrophils. These defensins were named human neutrophil peptides (HNP) 1-3 of the a-defensin family [10] . Subsequently, a fourth a-defensin was discovered in neutrophils, termed HNP-4 [11] [12] [13] . More recently, two additional a-defensins were described, termed human defensin 5 and 6 [14, 15] . HD-5 and HD-6 are stored in the granules of Paneth cells, specialized epithelial cells in the small intestine [16] .
Defensins are widely accepted to kill bacteria through pore formation in the microbial membrane, causing leakage of intracellular contents and cell lysis [17, 18] . The specific disruption of the bacterial membrane by defensins is believed to be driven by electrostatic attractions between these cationic peptides and the negatively charged membrane. However, alternative mechanisms for bacterial killing have been proposed, including membraneindependent mechanisms and targeting of intracellular compounds by defensins [19] [20] [21] .
Recent observations on the bacterial killing by human defensins could not fully be explained by the membrane-disruption model, suggesting a more nuanced mode of action. First, a-defensins were shown to preferentially kill Gram-positive bacteria, whereas bdefensins kill Gram-negative strains more effectively [22, 23] . However, human b-defensins carry more positive charges, indicating that cationicity of defensins alone does not explain this strainspecificity. Second, disruption of the membrane via stable pore formation is believed to require peptide structure. However, we and others have shown that bacterial killing by defensins can be structure-independent [24, 25] . Third, we recently observed that a-defensins composed entirely of D-amino acids show greatly reduced antibacterial activity against Staphylococcus aureus compared to the L-peptide, suggesting that the microbial membrane is not the sole target [26] . Here, we further examine the bacterial killing by a-defensins and provide evidence for an interaction with the bacterial target lipid II. 
Materials and methods

Materials
Chemicals used for solid phase peptide synthesis were obtained as described [27] . S. aureus ATCC 29213 was obtained from Microbiologics (St. Cloud, MN). The phospholipids palmitoyloleoyl-phosphatidylcholine (POPC), palmitoyl-oleoyl-phosphatidylglycerol (POPG) and dipalmitoyl-phosphatidyl choline (DPPC) were purchased from Avanti Polar Lipids (Alabaster, AL). 8-Aminonaphthalene-1,3,6-trisulfonic acid sodium salt (ANTS) and p-xylenebis(pyridinium) bromide (DPX) were from Molecular Probes (Eugene, OR). Poly-L-lysine (MW = 3800) was obtained from Sigma. Bacitracin, D-cycloserine and fosfomycine were purchased from Sigma, Calbiochem and LKT Laboratories respectively.
Solid phase peptide synthesis
Chemical synthesis and folding of defensins was carried out as described [27, 28] . The molecular mass of the peptides was verified by electrospray ionization mass spectrometry (ESI-MS) as described [27] . Peptide stock solutions prepared with water were quantified spectroscopically using molar extinction coefficients at 280 nm calculated according to the algorithm of Pace et al. [29] .
LUVs preparation
LUVs with the low molecular weight fluorophore/quencher pair (ANTS/DPX) encapsulated were prepared using the standard extrusion method. Specifically, phospholipids were dissolved in chloroform at a desired molar ratio, dried as a film by solvent evaporation. After removal of residual solvent, the lipid film was hydrated in the fluorescent solution containing 5 mM HEPES, 12.5 mM ANTS, 45 mM DPX, and 20 mM NaCl, pH 7.0, freezethawed for 10 cycles and extruded 10 times through 0.4-lm polycarbonate membranes. LUVs were separated from unencapsulated materials by gel filtration chromatography using a Sepharose CL-4B column eluted with 5 mM HEPES, 100 mM NaCl, pH 7.4 (highsalt). For leakage assays in a low-salt buffer, purified vesicles were further diluted with 5 mM HEPES containing 10 mM NaCl, pH 7.4.
Leakage assay
Leakage of ANTS from LUVs, monitored on a LS-55 Perkin Elmer luminescence spectrometer, was characterized by an increase in fluorescence, which was quenched by DPX when encapsulated together inside liposomes [30] . 270 ll ANTS/DPX-encapsulated LUVs (in either high-salt or low-salt buffers) were added to each well of a 96-well plate to a final lipid concentration of 600 lM. 30 ll H 2 O was added to the first well of each row as a blank, and 30 ll 2.5% (v/v) Triton X-100 to the last (twelfth) well as the control for 100% leakage. Upon addition of 30 ll of a twofold dilution series of defensin, the fluorescence signal was recorded at 515 nm with an excitation wavelength of 353 nm, 10 nm bandwidths and a 390 nm cut-off filter in the emission path. Percent leakage is expressed as:
where F t is the fluorescence determined at different time points after addition of defensin, F 0 is the background fluorescence of the ''blank" cells, and F 100 is the fluorescence of the control cells containing 0.25% Triton X-100.
Lipid II purification
Short-chain water-soluble lipid II containing a lipid tail of three isoprene units was generated and purified essentially as described [31] . Typically, M. flavus vesicles (120 lmol lipid-Pi) were incubated together with 500 lmol UDP-GlcNAc, 500 lmol UDP-Mur-NAC-pentapeptide and 400 lmol farnesyl phosphate in 100 mM Tris-HCl pH 8.0, 5 mM MgCl 2 . The incubation lasted 2 h at room temperature for 3-P. The synthesis of 3-lipid II was followed using RP-8 reversed phase TLC (Merck) developed in 75% methanol. For purification, the membranes were removed by centrifugation at 40 000Âg and the supernatant was collected and loaded on a C18 HPLC column and eluted with a linear gradient from 50 mM ammonium bicarbonate to 100% methanol in 30 min. Farnesyl-lipid II (3-lipid II) eluted at approximately 60% methanol. Its identity was confirmed by mass spectroscopy.
Surface plasmon resonance
Surface plasmon resonance binding experiments were carried out on a BIAcore T100 system (BIAcore Inc., Piscataway, NY) at 25°C. The assay buffer was 10 mM HEPES, 150 mM NaCl, 0.05% surfactant P20, pH 7.4 (±3 mM EDTA). L-HNP1 (780 RUs) or D-HNP1 (790 RUs) were immobilized on CM5 sensor chips using the amine-coupling chemistry recommended by the manufacturer.
Lipid II was introduced into the flow-cells at 30 ll/min in the running buffer. Association and dissociation were assessed for 300 and 600 s, respectively. Resonance signals were corrected for non-specific binding by subtracting the background of the control flowcell. After each analysis, the sensor chip surfaces were regenerated with 15 mM HCl for 30 s at a flow rate 100 ll/min, and equilibrated with the buffer prior to next injection. Binding isotherms were analyzed with manufacturer-supplied software for BIAcore T100 and/or GraphPad Prism 4.0.
Antibacterial activity assay
The antibacterial activity of HNP1 against S. aureus ATCC 29213 was carried out in a 96-well turbidimetric assay essentially as described previously [22] . Lipid II levels in S. aureus were manipulated by the addition of three different inhibitors of cell wall synthesis: bacitracin (250 lg/ml), D-cycloserine (64 lg/ml) and fosfomycine (250 lg/ml). Bacterial cultures were pre-treated with these compounds for 30 min under shaking at 37°C. Subsequently, cells were exposed to HNP1 peptide ranging from 256 to 1 lg/ml for 15 min, after which HNP1 activity was neutralized by the addition of Mueller Hinton broth. Bacterial growth was monitored for 12 h and data were analyzed as described [22] .
Results
Membrane lipid interaction of a-defensins
Defensins are believed to kill bacteria by permeabilizing the membrane, causing leakage of intracellular content and eventually cell lysis and death. We tested the ability of six human a-defensins to induce leakage of fluorophores encapsulated in LUVs (Fig. 1) . Fig. 1 shows typical time-dependent leakage curves for HNP1-4 and HD-5-6 with POPG LUVs at high and low-salt concentrations over a period of 24 h. All the six a-defensins tested at concentrations ranging from 0.19 to 100 lg/ml, whenever capable of inducing liposomal leakage, were fast acting as evidenced by a fluorescence plateau reached within the first hour. The plateau effect reflects the observation that at the start of the experiment the fractional fluorescence increases rapidly due to leakage of ANTS and DPV from the vesicles into the exterior solution, after which dilution removes the quenching effect of DPX. The observed differences between individual defensins over time likely reflect differences in the kinetics of induction of LUV leakage. Membrane activity of defensins invariably decreased at high-salt concentrations and varied significantly between the defensins tested.
Next, we examined the effects of negative surface charge on defensin-induced membrane leakage. We used HNP1, extensively in our laboratory [23, 26, 32, 33] , as a model for a-defensins in these experiments. To elucidate the role of electrostatic forces in defensin-induced membrane leakage, we prepared LUVs composed of the unsaturated lipid pair POPC (charge: 0) and POPG (charge: À1) at four different ratios, i.e., POPC:POPG = 1:0, 3:2, 2:3, and 0:1. As shown in Fig. 2A , leakage from LUVs became increasingly pronounced across the entire HNP1 concentration range as the content of the negatively charged lipid POPG increased from 0%, 40%, 60% to 100%, equivalent to a charge on the membrane surface of 0, À0.4, À0.6 and À1, respectively. LUVs composed solely of the neutral lipid POPC were resistant to the attack by HNP1 at all concentrations used, regardless of the incubation time. We recently reported that HNP1 composed entirely of D-amino acids (D-HNP1) was significantly less bactericidal than L-HNP1 against S. aureus [26] . We compared the ability of both L-and D-HNP1 to induce leakage from LUVs (DPPC/POPG (1:1)) and no significant difference in activity between the two enantiomers was found (Fig. 2B) .
Taken together, these findings suggest that defensin-induced permeabilization of lipid vesicles depends on electrostatic interaction, however varies greatly between different a-defensins. Most importantly, the ability of individual a-defensins to cause membrane leakage (Fig. 1) correlates poorly with their ability to kill bacteria [22] . For example, HNP-4, the most membrane active defensin in the panel of six (Fig. 1) , is ineffective against Gram-positive bacteria [22] . Vice versa, HNP1 and HD-5 are potently bactericidal, however display reduced, or in the case of HD-5 little membrane activity even at high concentrations. Finally, our observation that D-HNP1 and L-HNP1 disrupt LUVs equally efficiently suggests that native HNP1 preferentially interacts with a bacterial membrane component, possibly of chiral nature.
HNP1 binds to lipid II
Recently, a-defensins were shown to bind with high affinity to glycosylated proteins [34] and carbohydrates [35] . HNP1 kills Gram-positive bacteria very efficiently, however showed reduced membrane leakage, especially at high-salt concentrations. Based on these studies, we reasoned that defensins could interact with components of the bacterial cell wall or cytoplasmic membrane. We studied the possibility of an interaction between defensins and lipid II, a peptidoglycan precursor, for two reasons: (i) the Grampositive cell wall consists of a thick layer of peptidoglycan and (ii) lipid II is a known target for antibiotic peptides [36] . D-HNP1 and a linear form of HNP1 were studied also, since both linear as well as enantiomeric a-defensin peptides appeared less bactericidal against S. aureus, but equally bactericidal against E. coli [24, 26] . We used a surface plasmon resonance (SPR) approach to determine the binding of HNP1 to lipid II directly. Initial binding of L-HNP1, D-HNP1 and linear HNP1 to soluble lipid II immobilized on the chip surface was determined. As shown in Supplementary  Fig. 1, linear HNP1 1.08 Â 10 À5 M).
HNP1 functionally interacts with lipid II
To examine whether the observed interaction between HNP1 and lipid II is functionally relevant in the environment of the membrane, we determined the ability of HNP1 to kill S. aureus with altered levels of lipid II. Three different inhibitors of cell wall synthesis, fosfomycine, D-cycloserine, and bacitracin, were used to reduce the lipid II levels in S. aureus cells. Bacitracin binds directly to undecaprenyl-pyrophosphate, the portion of lipid II that remains in the membrane once GlcNAc-MurNAc is polymerized, and prevents its use in subsequent cycles of lipid II synthesis. Fosfomycine is an inhibitor of MurA, the enzyme responsible for the first step in peptidoglycan synthesis. D-Cycloserine inhibits both alanine racemase and D-Ala-D-Ala ligase, two enzymes required for the synthesis of the D-Ala-D-Ala dipeptide of lipid II. All three inhibitors thus block the synthesis of lipid II [37] . S. aureus cells were exposed to each of the lipid II synthesis inhibitors for 30 min and subsequently exposed to HNP1 at concentrations ranging from 256 to 1 lg/ml for 15 min (Fig. 4) . Following pre-treatment with lipid II biosynthesis inhibitors and exposure of HNP1 to the bacteria for 2 h, according to our original protocol [22] , we observed no difference in bacterial killing (data not shown). Most likely, the effects of any bacterial pre-treatments are negated by killing efficiency and kinetics of HNP1 during the prolonged, 2 h exposure to the bacteria. As observed previously, after 15 min, HNP1 efficiently killed S. aureus [38] . At peptide concentrations of 256 and 128 lg/ml, bacterial growth did not measurably recover after 12 h incubation and data points could not be plotted. Fosfomycine and D-cycloserine and in particular bacitracin treatment attenuated killing of S. aureus by HNP1 markedly. Taken together, these data indicate that efficient killing of S. aureus by HNP1 depends on membrane lipid II levels.
Discussion
Disruption of the functional integrity of the bacterial membrane is a common mode of action of many antibacterial compounds and is believed to be the primary mode of bacterial killing by defensins. An early study reported on the bactericidal activity of HNP1-3 against E. coli, suggesting a sequential permeabilization of the outer and inner membranes [18] . More recent observations on the bactericidal activity of a-defensins have expanded and nuanced these findings.
We and others reported that linear, unstructured defensins retained their antibacterial activity in a strain-selective manner [24, 39] . The activity of HD-5 against E. coli appeared structure-independent, whereas the unstructured peptide showed greatly reduced activity against S. aureus [24] . More recently, we observed that the D-forms of HNP1 and HD-5 were significantly less active than their native ATCC 29213 exposed to HNP1 at concentrations varying twofold from 1 to 256 lg/ ml. Bacteria were pre-treated with bacitracin (250 lg/ml), D-cycloserine (64 lg/ml) and fosfomycine (250 lg/ml) for 30 min under shaking at 37°C as indicated, followed by exposure to HNP1 for 15 min. Each curve is the mean of three separate experiments (±S.D.). Points scored as zero survival could not be plotted.
L-forms against S. aureus, but equally bactericidal against E. coli [26] . Combined, these findings suggested different bactericidal mechanisms of a-defensins against E. coli or S. aureus. In addition, these findings suggested a possible interaction between defensins and an unidentified cellular component of S. aureus. In this study, we find that HNP1 functionally interacts with lipid II, an essential precursor of cell wall synthesis [36] . A number of antibacterial compounds target lipid II, thus affecting cell wall synthesis or membrane function [36] . For example, the antibacterial action of nisin, an amphiphilic peptide produced by certain strains of Lactococcus lactis, is a result of its high affinity for lipid II as well as its ability to assemble into nisin-lipid II complexes [31] . Such complexes have the ability to form pores in the membrane, explaining the high efficacy of nisin [40] . Here, we show that bacterial killing by a-defensins depends on lipid II levels by blocking the synthesis of lipid II. All three lipid II synthesis inhibitors reduced bacterial killing, in particular when S. aureus cells were pre-treated with bacitracin. A similar observation was made recently in the case of nisin [37] . In this study, depolarization of the S. aureus membrane induced by nisin was suppressed by pretreatment of cells with lipid II inhibitors, especially by bacitracin. Interestingly, nisin and bacitracin share a common target in binding the lipid II molecule, both binding the pyrophosphate moiety of undecaprenyl-pyrophosphate [37, 40] . Since the antibacterial activity of both nisin and defensin was reduced most strongly by treatment with bacitracin, it is tempting to speculate that defensins, like nisin, may use lipid II as an initial binding target and perhaps even similarly disrupt the membrane via complex pore formation.
Our observation that HNP1 binds to lipid II partly rationalizes our previous findings on the strain-selective and structure-dependent difference in bactericidal activity of human a-defensins. However, questions still remain why a-defensins preferentially kill Gram-positive bacteria. For example, we found that D-HNP1 binds to lipid II with a fivefold weaker affinity than the L-form. This difference could be explained by the fact that lipid II itself is a chiral molecule. However, D-HNP1 was found to be $19 times weaker in S. aureus killing compared to L-HNP1 as judged by their respective vLD90 values, defined as the defensin concentration required to kill 90% of bacteria [26] . Defensins therefore may interact with other membrane components in addition to lipid II. Other possible interactions at the bacterial membrane could include negatively charged molecules such as (lipo)teichoic acid in the case of Gram-positive bacteria or lipopolysaccharide or teichoic acid in the case of Gram-negative bacteria. Precursors of teichoic acid synthesis are, like lipid II, undecaprenyl-linked [41] , and may therefore constitute a possible binding target for HNP1 also. In addition, we observed that bacterial killing by a-defensins correlates poorly with their lipid membrane activity. Nevertheless, increase of negative charge of the phospholipid headgroup increased HNP1 membrane activity, suggesting that bactericidal activity may involve direct defensin-lipid interactions. In summary, our findings suggest the inhibition of peptidoglycan synthesis through binding of lipid II as a novel mechanism of bacterial killing for defensins.
